Issue Date: December 5, 2016
Pfizer invests in U.S., eases up in Ireland
Pfizer is set to invest more than $200 million to build R&D and process development facilities in St. Louis County, Mo. The planned facilities will be used to advance biotherapeutics including vaccines, immuno-oncology therapies, monoclonal antibodies, and biosimilars. Pfizer expects construction to begin in 2017. Meanwhile, Pfizer says it will ease back on expansion plans in Clondalkin, Ireland, following the phase III clinical trial failure of its cholesterol-lowering drug candidate bococizumab, a proprotein convertase subtilisin . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society